Niacin for Fatty Liver: Evidence and Safety

Niacin for fatty liver is a topic attracting growing interest, particularly as researchers explore the role of NAD+ precursors in metabolic liver disease. Niacin (vitamin B3) has well-established effects on blood lipids and cellular energy metabolism, leading some to ask whether it could benefit those with fatty liver disease. This article examines the biological rationale, reviews the current clinical evidence, outlines important safety considerations, and explains how niacin fits alongside the lifestyle changes recommended by NICE and NHS guidelines for managing fatty liver disease.

What is fatty liver disease and how is it treated on the NHS?

Fatty liver disease, most commonly MASLD, is managed on the NHS primarily through lifestyle modification, as no drug is currently licensed in the UK specifically for this condition. NICE guideline NG49 recommends weight reduction, physical activity and control of cardiovascular risk factors.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, and it is broadly divided into two main types: metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD, the term still used in NICE guideline NG49) and alcohol-related liver disease (ALD). MASLD is now the most common chronic liver condition in the UK, closely linked to obesity, type 2 diabetes, high blood pressure and raised blood lipids. In its early stages it is often silent, but it can progress through stages of inflammation (steatohepatitis), fibrosis and, in some cases, cirrhosis.

NICE guideline NG49 (Non-alcoholic fatty liver disease: assessment and management) recommends that MASLD is managed primarily through lifestyle modification rather than medication, as no drug is currently licensed in the UK specifically for this condition.^[1] Assessment typically involves liver function blood tests and a FIB-4 score for initial fibrosis risk stratification. NICE NG49 recommends the Enhanced Liver Fibrosis (ELF) test for assessing advanced fibrosis, and many Integrated Care Board (ICB) pathways also use FIB-4 or the NAFLD Fibrosis Score as a first-line tool.^[2] Where indicated, transient elastography (FibroScan) or liver biopsy may follow. Referral to a hepatologist is recommended for those with significant fibrosis or diagnostic uncertainty.

On the NHS, management focuses on weight reduction, physical activity, control of cardiovascular risk factors and optimisation of conditions such as type 2 diabetes and dyslipidaemia. NICE NG49 and European guidelines support a target weight loss of at least 5 to 10 per cent of body weight, which evidence suggests can meaningfully reduce liver fat and inflammation; losses of 10 per cent or more may lead to regression of fibrosis in some patients.^[1][14] Alcohol-related liver disease requires additional support around alcohol cessation, and specialist referral pathways exist for both conditions through GP surgeries and hepatology services.

Seek urgent medical attention if you develop new jaundice (yellowing of the skin or eyes), vomiting blood or passing black tarry stools, confusion or drowsiness, severe pain in the upper right abdomen with fever, or rapidly increasing abdominal swelling. These features may indicate serious liver decompensation and require same-day assessment.

How does niacin work, and could it help a fatty liver?

Niacin may theoretically reduce hepatic fat by inhibiting DGAT2 and boosting NAD+ levels, but this evidence is largely mechanistic and unconfirmed in large clinical trials. None of the niacin-related agents is licensed in the UK for treating fatty liver disease.

Niacin (vitamin B3) is a water-soluble B vitamin that plays a central role in cellular energy metabolism, and at pharmacological doses it has well-established effects on blood lipids, including raising HDL cholesterol and lowering triglycerides. It exists in two main forms: nicotinic acid and nicotinamide (niacinamide), which share some metabolic functions but differ in their pharmacological effects at higher doses. Nicotinic acid is the form historically used as a lipid-modifying agent.

The theoretical rationale for niacin in fatty liver disease relates to several mechanisms. First, preclinical and early human studies suggest that niacin may inhibit hepatic diacylglycerol acyltransferase 2 (DGAT2), an enzyme involved in triglyceride synthesis within the liver, which could in principle reduce hepatic fat accumulation; however, this evidence is largely mechanistic and has not been confirmed in large clinical trials. Second, niacin is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for mitochondrial function and cellular repair. Declining NAD+ levels have been implicated in metabolic liver disease in preclinical models, and supplementation with NAD+ precursors is an active area of early-phase research. Third, niacin's lipid-lowering properties may indirectly benefit the metabolic environment that drives MASLD.

It is important to distinguish between physiological doses of niacin found in food and multivitamins, pharmacological doses used historically for dyslipidaemia, and newer NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are structurally related but not identical. Each has a different evidence base and safety profile. None of these agents is currently licensed in the UK by the MHRA for the treatment of fatty liver disease, and they should not be used as a substitute for established lifestyle and medical management.

What does the current evidence say about niacin and liver health?

Current evidence does not support routine use of niacin for fatty liver disease, with most data from small studies and animal models rather than large randomised controlled trials. The HPS2-THRIVE trial raised significant safety concerns, contributing to the withdrawal of niacin-based lipid therapies in the UK.

The current evidence on niacin specifically for fatty liver disease is limited and does not yet support its routine use as a treatment. Most of the available data come from small mechanistic studies, animal models and early-phase human trials rather than large, well-powered randomised controlled trials. No regulatory body, including the MHRA, NICE or the EMA, has approved niacin or its derivatives for the treatment of MASLD or any other form of fatty liver disease.

Some small human studies have explored nicotinamide riboside (NR) supplementation and its effect on hepatic NAD+ levels and metabolic markers. Results have been mixed: while some trials have demonstrated increases in NAD+ concentrations in blood and tissue, improvements in liver fat or liver enzyme levels have not been consistently demonstrated. A randomised trial published in Nature Communications in 2020 (Dollerup et al.) found that NR supplementation raised NAD+ metabolites in healthy overweight adults but did not significantly reduce liver fat as measured by magnetic resonance spectroscopy.

For pharmacological nicotinic acid, the picture is complicated by the fact that high-dose niacin has historically been associated with hepatotoxicity (discussed further below), which limits enthusiasm for its use in people who already have liver disease. The HPS2-THRIVE trial (Landray et al., New England Journal of Medicine, 2014), which examined extended-release niacin combined with laropiprant in people with established cardiovascular disease, did not demonstrate cardiovascular benefit and raised safety concerns including increased rates of infection, new-onset diabetes and myopathy when combined with statins.^[3][4] These findings contributed to the withdrawal of niacin-based lipid therapies from widespread clinical use in the UK. Overall, while the biological rationale is plausible, the clinical evidence base for niacin in fatty liver disease remains insufficient to recommend it outside of a research setting.

Are there safety concerns with taking niacin if you have liver disease?

High-dose niacin carries a well-documented risk of hepatotoxicity and is contraindicated or requires caution in hepatic impairment, making it particularly concerning for those with existing liver disease. Adverse effects include flushing, raised blood glucose, raised uric acid and liver enzyme elevation.

High-dose niacin carries a well-documented risk of hepatotoxicity, and this is a particularly important consideration for anyone who already has liver disease. The UK SmPC for nicotinic acid preparations (such as Niaspan, available on the MHRA's medicines compendium) lists hepatic impairment as a contraindication or a reason for caution depending on severity, and liver function monitoring is recommended during treatment. Evidence from clinical studies and case series suggests that hepatotoxicity appears to be more common with sustained-release formulations of nicotinic acid than with immediate-release forms, though both carry risk at pharmacological doses.^[5]

Common adverse effects of niacin at higher doses include:

• Flushing: a prostaglandin-mediated skin reaction causing redness, warmth and itching, typically affecting the face and upper body^[16]

• Gastrointestinal symptoms: nausea, vomiting, abdominal discomfort and diarrhoea

• Raised blood glucose: niacin can impair insulin sensitivity, which is particularly relevant in people with type 2 diabetes or metabolic syndrome, conditions that frequently coexist with MASLD^[8]

• Raised uric acid: niacin can precipitate or worsen gout

• Liver enzyme elevation: even at moderate doses, transaminase rises have been reported

Important interactions should also be considered. Combining high-dose niacin with a statin increases the risk of myopathy and rhabdomyolysis, as highlighted by the HPS2-THRIVE trial findings.^[3][6] Niacin can worsen glycaemic control and may alter the effect of glucose-lowering medicines. It can also raise uric acid levels, potentially interacting with gout treatments. Alcohol may worsen flushing and increase the risk of liver toxicity. Anyone taking any of these medicines should seek clinician advice before using high-dose niacin supplements.

Nicotinamide (niacinamide) at supplemental doses is generally considered safer than nicotinic acid and does not cause flushing, but very high doses have also been associated with liver enzyme abnormalities. High-dose niacin and its derivatives are generally avoided during pregnancy and breastfeeding unless specifically advised by a specialist; anyone who is pregnant, planning a pregnancy or breastfeeding should discuss supplement use with their GP or midwife before starting.

Anyone with existing liver disease, whether MASLD, ALD or another hepatic condition, should speak to their GP before taking any niacin-containing supplement above standard dietary levels. If you experience jaundice, dark urine, severe abdominal pain or unexplained fatigue while taking any supplement, contact your GP promptly. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What lifestyle changes are recommended alongside any supplement use?

Lifestyle modification, including 5 to 10 per cent weight loss, a Mediterranean-style diet and at least 150 minutes of moderate aerobic exercise per week, is the most evidence-based intervention for fatty liver disease. These measures should be discussed with a GP or specialist dietitian and form the foundation of any management plan.

Lifestyle modification remains the most evidence-based intervention for fatty liver disease, and it should be the foundation of any management plan, whether or not supplements are being considered. NICE guideline NG49 and European guidelines (EASL/EASD/EASO) support a sustained reduction in body weight of 5 to 10 per cent as associated with meaningful reductions in liver fat; losses of 10 per cent or more may lead to regression of fibrosis in some patients. Weight loss should be achieved gradually through a combination of dietary change and increased physical activity rather than very low-calorie diets alone, unless supervised by a specialist.

Dietary recommendations for MASLD align broadly with a Mediterranean-style eating pattern, which is rich in vegetables, legumes, wholegrains, oily fish and olive oil, and low in ultra-processed foods, refined carbohydrates, added sugars and saturated fat. Fructose-sweetened drinks and foods are of particular concern, as fructose is metabolised almost exclusively in the liver and contributes directly to hepatic fat accumulation. Alcohol should be minimised or avoided entirely, even in MASLD where alcohol is not the primary cause. The UK Chief Medical Officers advise that if people choose to drink, they should aim to keep consumption to no more than 14 units per week spread across three or more days, with several alcohol-free days; in MASLD, your clinician may advise lower intake or complete abstinence depending on your individual circumstances.^[9]

The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic exercise per week, with the addition of resistance training where possible.^[10][11] Both aerobic and resistance exercise have been shown to reduce liver fat independently of weight loss.^[12][13] Smoking cessation and optimisation of cardiovascular risk factors, including blood pressure and blood glucose, are also important components of care.

For those seeking structured support with weight management, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, alongside a range of evidence-based options. Regardless of any supplement use, these lifestyle measures should be discussed with a GP or specialist dietitian to ensure they are tailored to individual health needs.

Scientific References

1. Non-alcoholic fatty liver disease: assessment and management (NG49).
2. NG49 chapter: Assessment for advanced liver fibrosis in people with MASLD.
3. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients (HPS2-THRIVE).
4. Serious Adverse Effects of Extended-release Niacin/Laropiprant (HPS2-THRIVE).
5. Sustained-release vs immediate-release niacin in hypercholesterolaemic patients (McKenney et al.).
6. Treatment of hyperlipidaemia with combined niacin-statin therapy (Guyton).
7. Risk for Myopathy With Statin Therapy in High-Risk Patients (Ballantyne et al.).
8. Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control (Elam et al.).
9. Alcohol consumption: advice on low risk drinking – UK Chief Medical Officers.
10. Physical activity guidelines: UK Chief Medical Officers' report.
11. Physical activity guidelines for adults aged 19 to 64.
12. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomized Controlled Trials.
13. Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial.
14. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review.
15. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
16. Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing.
17. Pelzont (nicotinic acid/laropiprant) EPAR public assessment report.

Frequently Asked Questions